PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.29%
EBIT growth below 50% of TRAW's 100.00%. Michael Burry would suspect deeper competitive or cost structure issues.
3.29%
Positive operating income growth while TRAW is negative. John Neff might view this as a competitive edge in operations.
27.01%
Positive net income growth while TRAW is negative. John Neff might see a big relative performance advantage.
26.90%
Positive EPS growth while TRAW is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
26.90%
Positive diluted EPS growth while TRAW is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.31%
Positive OCF growth while TRAW is negative. John Neff would see this as a clear operational advantage vs. the competitor.
3.31%
Positive FCF growth while TRAW is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.36%
Negative 10Y OCF/share CAGR while TRAW stands at 77.68%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-12.36%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-12.36%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
44.63%
Below 50% of TRAW's 98.31%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
44.63%
Positive 5Y CAGR while TRAW is negative. John Neff might view this as a strong mid-term relative advantage.
44.63%
Positive short-term CAGR while TRAW is negative. John Neff would see a clear advantage in near-term profit trajectory.
-80.42%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-80.42%
Negative 5Y equity/share growth while TRAW is at 10162.80%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-80.42%
Negative 3Y equity/share growth while TRAW is at 7609.85%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Asset growth well under 50% of TRAW's 81849.33%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-16.23%
We have a declining book value while TRAW shows 59775.48%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
14.30%
Debt growth of 14.30% while TRAW is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-4.62%
We cut SG&A while TRAW invests at 61301.60%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.